Sanofi has committed to donate 100 million doses of hydroxychloroquine across 50 countries to support fight against Covid-19.

The company increased its production capacity by 50% and is making preparations to further boost production over the coming months.

If ongoing clinical trials demonstrate hydroxychloroquine’s safety and efficacy in Covid-19, Sanofi will continue to donate the drug to governments and hospitals.

Sanofi CEO Paul Hudson said: “It is critical that international authorities, local governments, manufacturers, and all the other players involved in the hydroxychloroquine chain work together in a coordinated manner to ensure all patients who may benefit from this potential treatment can access it.

“If the trials prove positive, we hope our donation will play a critical role for patients.”

Meanwhile, the US National Institutes of Health started the ORCHID Study of hydroxychloroquine to treat adults hospitalised with Covid-19.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.